SCHEMBL2954699

SCHEMBL2954699

O=C(N1CCN(c2ccccc2)CC1)n1c(=O)c2ccc(F)cc2n1C(=O)N1CCN(c2ccccc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.49
ALDH1A1 P00352 1/20 0.49
RECQL P46063 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.47
AKR1C3 P42330 3/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MAPK1 P28482 3/20 0.45
USP2 O75604 2/20 0.45
ALOX15 P16050 1/20 0.44
GLA P06280 1/20 0.44
HTT P42858 2/20 0.44
THRB P10828 2/20 0.44
TP53 P04637 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SLC6A7 Q99884 1/20 0.43
TSHR P16473 3/20 0.43
MAPT P10636 3/20 0.43
RAB9A P51151 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2957832 0.78 RAB9A (0.40) LMNAALDH1A1SMN1; SMN2HTTTHRB
SCHEMBL31596689 0.73 MAPT (0.49) LMNAALDH1A1SMN1; SMN2THRBTP53
SCHEMBL2961336 0.72 ALOX15 (0.52) LMNAALDH1A1RECQLSMN1; SMN2AKR1C3
SCHEMBL27792690 0.72 AKR1C3 (0.82) LMNAALDH1A1AKR1C3CYP2C9CYP2C19
SCHEMBL16242493 0.69 FAAH (0.42) LMNAALDH1A1RECQLSMN1; SMN2AKR1C3
SCHEMBL30976438 0.69 MEN1 (0.57) LMNAALDH1A1RECQLSMN1; SMN2USP2
SCHEMBL27607283 0.69 AKR1C3 (0.83) LMNAALDH1A1SMN1; SMN2AKR1C3MAPK1
SCHEMBL2735943 0.68 HRH4 (0.70) LMNAALDH1A1CYP2C19MEN1KMT2A
SCHEMBL19889837 0.68 AKR1C3 (0.43) LMNAALDH1A1SMN1; SMN2AKR1C3CYP2C9
SCHEMBL19889821 0.67 AKR1C3 (0.59) LMNAALDH1A1AKR1C3CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937648-B1 DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS SANOFI SA (FR) 2014-11-26 EP disclosed
US-8357698-B2 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI (FR) 2013-01-22 US disclosed
US-20100286133-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI-AVENTIS (FR) 2010-11-11 US disclosed
US-7772268-B2 inhibitors of hormone-sensitive lipase and/or endothelial lipase; for treatment of diabetes mellitus, dyslipidemia and atherosclerotic disorders SANOFI-AVENTIS (FR) 2010-08-10 US disclosed
US-20080287448-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI-AVENTIS (FR) 2008-11-20 US disclosed
EP-1937648-A1 DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS sanofi-aventis (FR) 2008-07-02 EP disclosed
WO-2007042178-A1 DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS SANOFI-AVENTIS (DE) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287448-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors PNLIP, DAGLA, MGLL LMNA 1799/4885ALDH1A1 959/4885RECQL 235/4885
US-20100286133-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors PNLIP, DAGLA, MGLL LMNA 1799/4885ALDH1A1 959/4885RECQL 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.